SRX Global acquires stake in Vistagen Therapeutics
VTGN•SRX Global takes minority stake in Vistagen
SRX Global acquired a stake in Vistagen Therapeutics, taking a minority equity position in the Nasdaq-listed biotech.
The investment targets Vistagen’s late-stage neuroscience pipeline built around intranasal “pherine” product candidates.
SRX Global sees Vistagen shares as undervalued
SRX Global described Vistagen shares as undervalued, signaling plans for engagement with management and the board on value creation.
